Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

17.12 -0.13 (-0.75%)
Streaming Delayed Price Updated: 1:24 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA Pharmaceuticals's Earnings: A Preview
Via Benzinga
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else? 
Via Benzinga
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
Via Benzinga
1 Top Biotech Stock to Buy in March
This biotech could land a major regulatory approval this month. 
Via The Motley Fool
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older. 
Via Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on... 
Via Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of... 
Via Benzinga
Analysts See Steady Growth For Acadia Pharma's Nuplazid
Via Benzinga
3 Nasdaq Stocks on Watch This Week
These three Nasdaq stocks are poised to make big moves in the coming week. 
Via The Motley Fool
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
From Kahn Swick & Foti, LLC
Via Business Wire
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Earnings Preview For ACADIA Pharmaceuticals
Via Benzinga
Analyst Expectations for ACADIA Pharmaceuticals's Future
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.